Immunosuppression for the treatment of pulmonary hypertension in patients with systemic lupus erythematosus: A systematic review

Bruera, Sebastian; Sreedhar, Arsha; Agarwal, Sandeep K.; Muthukumar, Varsha; Geng, Yimin; López-Olivo, María A.

doi:10.1111/1756-185x.14706

Cited by 4 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with SLE have a variety of clinical presentations, such as facial butterfly erythema, Raynaud's phenomenon, and oral mucosal ulcers 2 . Genetic, endocrine, immune abnormalities and some environmental factors are reported to be related to the pathogenesis of SLE 3 . Despite considerable progress made in the treatment of SLE in the last few years, it is crucial to discover precise therapeutic targets to improve early screening and prognostic assessment of patients.…”

Section: Introductionmentioning

confidence: 99%

Relationship between SHP2 gene polymorphisms and systemic lupus erythematosus risk

Zhou

Yang

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Objective Systemic lupus erythematosus (SLE) is a complex autoimmune disorder. SHP2, a non‐transmembrane member of the protein tyrosine phosphatase (PTP) family, can be involved in multiple signaling pathways in inflammatory response. To date, it remains to be investigated whether polymorphisms in the SHP2 gene are correlated with SLE in the Chinese Han population. Method A study comprising 320 SLE patients and 400 healthy individuals was performed. Three single nucleotide polymorphisms (rs4767860, rs7132778, rs7953150) of the SHP2 gene were genotyped using the Kompetitive Allele‐Specific Polymerase Chain Reaction method. Results Genotypes of rs4767860 (AA, AG + AA) and rs7132778 (AA, AC + AA), and alleles of rs4767860 (A) and rs7132778 (A) were associated with SLE risk. Genotype AA of rs7132778 and allele A of rs7132778 and rs7953150 were associated with oral ulcers in SLE patients. Allele C of rs7132778 and genotype AA and allele A of rs7953150 were associated with pyuria. Patients who carried AA genotype and allele A of rs7953150 are more likely to develop hypocomplementemia. AA and AG genotype frequencies are more raised in patients with SLE with alopecia than in those without alopecia. Patients who carried AA and AG genotypes of rs4767860 had elevated C‐reactive protein levels. Conclusion Gene polymorphisms of SHP2 (rs4767860, rs7132778) are relevant to SLE susceptibility.

show abstract

Section: Introductionmentioning

confidence: 99%

Relationship between SHP2 gene polymorphisms and systemic lupus erythematosus risk

Zhou

Yang

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

Innovations in the care of childhood interstitial lung disease associated with connective tissue disease and immune‐mediated disorders

Samad,

Wobma,

Casey

2024

Pediatric Pulmonology

View full text Add to dashboard Cite

Childhood interstitial lung disease (chILD) associated with connective tissue and immune mediated disorders is the second most common chILD diagnostic category. As knowledge of the molecular and genetic underpinnings of these rare disorders advances, the recognized clinical spectrum of associated pulmonary manifestations continues to expand. Pulmonary complications of these diseases, including ILD, confer increased risk for morbidity and mortality and contribute to increased complexity for providers tasked with managing the multiple organ systems that can be impacted in these systemic disorders. While pulmonologists play an important role in diagnosis and management of these conditions, thankfully they do not have to work alone. In collaboration with a multidisciplinary team of subspecialists, the pulmonary and other systemic manifestations of these conditions can be managed effectively together. The goal of this review is to familiarize the reader with the classic patterns of chILD and other pulmonary complications associated with primary immune‐mediated disorders (monogenic inborn errors of immunity) and acquired systemic autoimmune and autoinflammatory diseases. In addition, this review will highlight current, emerging, and innovative therapeutic strategies and will underscore the important role of multidisciplinary management to improving outcomes for these patients.

show abstract

Pulmonary Hypertension in Connective Tissue Diseases Other than Systemic Sclerosis

Budhram,

Weatherald,

Humbert

2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is a known complication of certain connective tissue diseases (CTDs), with systemic sclerosis (SSc) being the most common in the Western world. However, PH in association with non-SSc CTD such as systemic lupus erythematous, mixed connective tissue disease, and primary Sjögren's syndrome constitutes a distinct subset of patients with inherently different epidemiologic profiles, pathophysiologic mechanisms, clinical features, therapeutic options, and prognostic implications. The purpose of this review is to inform a practical approach for clinicians evaluating patients with non-SSc CTD-associated PH.The development of PH in these patients involves a complex interplay between genetic factors, immune-mediated mechanisms, and endothelial cell dysfunction. Furthermore, the broad spectrum of CTD manifestations can contribute to the development of PH through various pathophysiologic mechanisms, including intrinsic pulmonary arteriolar vasculopathy (pulmonary arterial hypertension, Group 1 PH), left-heart disease (Group 2), chronic lung disease (Group 3), chronic pulmonary artery obstruction (Group 4), and unclear and/or multifactorial mechanisms (Group 5). The importance of diagnosing PH early in symptomatic patients with non-SSc CTD is highlighted, with a review of the relevant biomarkers, imaging, and diagnostic procedures required to establish a diagnosis.Therapeutic strategies for non-SSc PH associated with CTD are explored with an in-depth review of the medical, interventional, and surgical options available to these patients, emphasizing the CTD-specific considerations that guide treatment and aid in prognosis. By identifying gaps in the current literature, we offer insights into future research priorities that may prove valuable for patients with PH associated with non-SSc CTD.

show abstract

Immunosuppression for the treatment of pulmonary hypertension in patients with systemic lupus erythematosus: A systematic review

Cited by 4 publications

References 22 publications

Relationship between SHP2 gene polymorphisms and systemic lupus erythematosus risk

Relationship between SHP2 gene polymorphisms and systemic lupus erythematosus risk

Innovations in the care of childhood interstitial lung disease associated with connective tissue disease and immune‐mediated disorders

Pulmonary Hypertension in Connective Tissue Diseases Other than Systemic Sclerosis

Contact Info

Product

Resources

About